London’s shrinking stock market suffered a fresh setback after British drugmaker Indivior said it could move its primary listing to the US

The London stock market, already experiencing a contraction, encountered another obstacle as British pharmaceutical company Indivior Plc announced it is contemplating transferring its primary listing to the United States.

Following the announcement, Indivior's share price witnessed a significant rise on Thursday. The company is initiating discussions with shareholders about the potential relocation scheduled for the summer of this year. Indivior believes that such a move would not only broaden its investor base and increase analyst coverage but also potentially secure its inclusion in major US stock indexes.

This development reflects the broader trend of companies seeking listings in markets they perceive as more beneficial for growth and visibility, posing a challenge to London's financial market's attractiveness to global corporations.